DUBLIN, Ireland, Dec. 12, 2016 (GLOBE NEWSWIRE) — Nexvet Biopharma (Nasdaq:NVET) today announced it has initiated a pivotal field efficacy and safety study of frunevetmab, the Company’s anti-nerve growth factor (NGF) monoclonal antibody (mAb) therapy which is being developed as a monthly subcutaneous injectable for the control of pain associated with osteoarthritis in cats. Nexvet expects to report data […]
By Heather Mack December 12, 2016 – link here SHARE 66 Melbourne, Australia-based smart inhaler company Adherium has been selected to supply the technology for a multi-country research program in Europe that will seek to establish whether home monitoring and mobile health tools can be used to manage asthma. Adherium’s Smartinhaler technology, which uses sensors to track […]
With nearly 40 published peer-reviewed journal articles under its belt, Adherium is hoping that the latest clinical data which underlines the ability of the company’s Smartinhaler to improve outcomes for children with poorly controlled asthma should boost the pairing of digital technologies with drugs. Download the press release here Or visit Medtech Insight
Tuesday October 25, 2016 SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a biotechnology company focused on the development and commercialization of novel bacteriophage-based antibacterial therapeutics, today announced topline results from its Phase 1 trial to evaluate the safety and tolerability of AB-SA01, its proprietary investigational phage cocktail targeting Staphylococcus aureus (S. aureus) infections in patients suffering […]
Monday 24 October 2016. 24 October 2016: Rex Bionics Plc (AIM: RXB), the pioneer of the REX Robot technology that enhances the mobility of wheelchair users, is pleased to announce the start of a new clinical trial treating patients who have had a stroke or brain injury, with Robot-Assisted Physiotherapy with REX. The trial is being […]
Tuesday, September 13, 2016. Link here. NYSEMKT:APHB SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced topline data from a Phase 1 trial to evaluate the safety and tolerability of AB-SA01, its proprietary investigational phage cocktail targeting Staphylococcus aureus (S. aureus) infections. […]
Monday, September 12, 2016. Link here. NYSEMKT:APHB SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, announced the publication of data from a preclinical study conducted by its collaborators at the University of Leicester demonstrating the therapeutic and prophylactic efficacy of AmpliPhi’s proprietary phage […]
Northridge, CA, Perth, Australia and London, United Kingdom – 2 September 2016 Link here.
1 September 2016: Link here. Adherium Limited (ASX:ADR), a global leader in digital health technologies that address sub-optimal medication use in chronic disease, today announced Mr Thomas Lynch as Adherium’s new Chairman, and Dr Doug Wilson as Adherium’s executive Medical Director. Mr Lynch’s appointment follows a global search for a high profile Director with broad […]